Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS)
NIVO-IPI is linked with a broader range of immune-related toxicities, whereas NIVO-RELA presents higher cardiac-specific risks. These findings emphasize the need for tailored AE monitoring based on treatment selection.
Authors
- Jiawei Wang (ORCID: https://orcid.org/0000-0001-5940-8113)
- Zhihui Song
- Ente Wang (ORCID: https://orcid.org/0000-0001-8096-3154)
- Dong Wang (ORCID: https://orcid.org/0000-0002-6107-7023)
- Shanshan Xu (ORCID: https://orcid.org/0000-0001-6354-3860)
Institutions
- Beijing Tongren Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-07-19
- DOI
- https://doi.org/10.1186/s12885-025-14546-6
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05